Statins and hepatotoxicity : Focus on patients with fatty liver von CHALASANI, Naga

Volltext

Randomised clinical study: GR‐MD‐02, a galectin‐3 inhibitor, vs. placebo in patients having non‐alcoholic steatohepatitis with advanced fibrosis von Harrison, S. A., Marri, S. R., Chalasani, N., Kohli, R., Aronstein, W., Thompson, G. A., Irish, W., Miles, M. V., Xanthakos, S. A., Lawitz, E., Noureddin, M., Schiano, T. D., Siddiqui, M., Sanyal, A., Neuschwander‐Tetri, B. A., Traber, P. G.

Volltext

Comparative analysis of portal hepatic infiltrating leucocytes in acute drug‐induced liver injury, idiopathic autoimmune and viral hepatitis von Foureau, D. M., Walling, T. L., Maddukuri, V., Anderson, W., Culbreath, K., Kleiner, D. E., Ahrens, W. A., Jacobs, C., Watkins, P. B., Fontana, R. J., Chalasani, N., Talwalkar, J., Lee, W. M., Stolz, A., Serrano, J., Bonkovsky, H. L.

Volltext

NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non‐HDL‐C levels von Corey, K. E., Vuppalanchi, R., Wilson, L. A., Cummings, O. W., Chalasani, N.

Volltext

Randomised clinical trial: a leucine‐metformin‐sildenafil combination (NS‐0200) vs placebo in patients with non‐alcoholic fatty liver disease von Chalasani, N., Vuppalanchi, R., Rinella, M., Middleton, M. S., Siddiqui, M. S., Barritt, A. S., Kolterman, O., Flores, O., Alonso, C., Iruarrizaga‐Lejarreta, M., Gil‐Redondo, R., Sirlin, C. B., Zemel, M. B.

Volltext

Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non‐alcoholic steatohepatitis von Vilar‐Gomez, E., Calzadilla‐Bertot, L., Friedman, S. L., Gra‐Oramas, B., Gonzalez‐Fabian, L., Villa‐Jimenez, O., Lazo‐del Vallin, S., Diago, M., Adams, L. A., Romero‐Gomez, M., Chalasani, N.

Volltext

Editorial: treating the liver to treat the kidney in non‐alcoholic steatohepatitis – authors' reply von Vilar‐Gomez, E., Chalasani, N.

Volltext

Serum proteomic profiling in patients with drug-induced liver injury von Bell, L. N., Vuppalanchi, R., Watkins, P. B., Bonkovsky, H. L., Serrano, J., Fontana, R. J., Wang, M., Rochon, J., Chalasani, N.

Volltext

A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease von Eaton, J. E., Juran, B. D., Atkinson, E. J., Schlicht, E. M., Xie, X., Andrade, M., Lammert, C. S., Luketic, V. A., Odin, J. A., Koteish, A. A., Kowdley, K. V., Chopra, K. B., Hirschfield, G. M., Chalasani, N. P., Lazaridis, K. N.

Volltext

Non-Alcoholic Steatohepatitis Resolution is Associated with Improvements in LDL Size and Phenotype von Corey, K, Wilson, L, Chung, R, Krauss, R, Chalasani, N

Volltext

Duloxetine hepatotoxicity: a case‐series from the drug‐induced liver injury network von Vuppalanchi, R., Hayashi, P. H., Chalasani, N., Fontana, R. J., Bonkovsky, H., Saxena, R., Kleiner, D., Hoofnagle, J. H.

Volltext

Patients with Autoimmune Hepatitis Report Lower Lifetime Coffee Consumption von Lammert, Craig, Chalasani, Sai N., Green, Kelsey, Atkinson, Elizabeth, McCauley, Bryan, Lazaridis, Konstantinos N.

Volltext

The diagnostic accuracy of vibration controlled transient elastography for cirrhosis in subjects with nonalcoholic fatty liver disease von Siddiqui, M.S, Vuppulanchi, R, Van Natta, M, Brandman, D, Tonascia, J.T, Chalasani, N, Middleton, M.S, Sanyal, A.J

Volltext

Evaluation of SOMAscan as a discovery platform to identify noninvasive protein biomarkers for diagnosis and monitoring of NASH von Lai, M., Libermann, T., Charlton, M., Diehl, A.M., Ngo, L., Dillon, S., Lawitz, E., Chalasani, N., Hameed, B., Caldwell, S., Rinella, M., Nguyen, T., Billin, A., Djedjos, S., Subramanian, M., Myers, R., Goodman, Z., Loomba, R., Afdhal, N.

Volltext

Environmental risk factors are associated with autoimmune hepatitis von Lammert, Craig, Chalasani, Sai N., Atkinson, Elizabeth J., McCauley, Bryan M., Lazaridis, Konstantinos N.

Volltext

LP15 : Separate and combined effects of obeticholic acid and weight loss in nonalcoholic steatohepatitis (NASH) von Hameed, B, Terrault, N, Gill, R, Loomba, R, Chalasani, N, Hoofnagle, J.H, Van Natta, M.L

Volltext

P1131 : Autoimmune hepatitis-like drug induced liver injury von de Boer, Y.S, Kosinski, A.S, Urban, T.J, Zhao, Z, Long, N, Chalasani, N, Hoofnagle, J.H

Volltext

1332 SERUM HEPCIDIN LEVELS IN THE MORBIDLY OBESE PATIENTS UNDERGOING BARIATRIC SURGERY von Vuppalanchi, R, Konrad, R, Chalasani, N

Volltext

LP18 : Obeticholic acid for NASH: benefits in a high risk subgroup and the effects of concomitant statin use von Neuschwander-Tetri, B, Sanyal, A, Loomba, R, Chalasani, N, Kowdley, K, Abdelmalek, M, Brunt, E, Shapiro, D

Volltext

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterol... von Chalasani, Naga, Younossi, Zobair, Lavine, Joel E., Diehl, Anna Mae, Brunt, Elizabeth M., Cusi, Kenneth, Charlton, Michael, Sanyal, Arun J.

Volltext